[go: up one dir, main page]

PE20190402A1 - IMPROVED TENELIGLIPTIN AND METFORMIN COMPOSITION AND PROCESS TO PREPARE IT - Google Patents

IMPROVED TENELIGLIPTIN AND METFORMIN COMPOSITION AND PROCESS TO PREPARE IT

Info

Publication number
PE20190402A1
PE20190402A1 PE2019000305A PE2019000305A PE20190402A1 PE 20190402 A1 PE20190402 A1 PE 20190402A1 PE 2019000305 A PE2019000305 A PE 2019000305A PE 2019000305 A PE2019000305 A PE 2019000305A PE 20190402 A1 PE20190402 A1 PE 20190402A1
Authority
PE
Peru
Prior art keywords
teneligliptin
metformin
prepare
improved
composition
Prior art date
Application number
PE2019000305A
Other languages
Spanish (es)
Inventor
Esteban Alejandro Fiore
Original Assignee
Rhein Siegfried Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61196457&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20190402(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhein Siegfried Sa De Cv filed Critical Rhein Siegfried Sa De Cv
Publication of PE20190402A1 publication Critical patent/PE20190402A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Referido a una composicion farmaceutica de administracion oral que comprende la combinacion de dos hipoglucemiantes, teneligliptina y metformina, aceptables para el tratamiento de diabetes mellitus tipo 2. Dicha composicion es obtenida por granulacion humeda, utilizando metformina molida a polvo fino y baja carga de excipientes, consistentes en un aglutinante como povidona y estearato de magnesio como lubricante; lo cual mejora notablemente la compresibilidad de la misma, permitiendo a su vez optimizar las condiciones operativas.Referring to a pharmaceutical composition for oral administration that comprises the combination of two hypoglycemic agents, teneligliptin and metformin, acceptable for the treatment of type 2 diabetes mellitus. Said composition is obtained by wet granulation, using metformin ground to fine powder and low load of excipients. consisting of a binder such as povidone and magnesium stearate as a lubricant; which notably improves its compressibility, allowing in turn to optimize operating conditions.

PE2019000305A 2016-08-17 2017-06-23 IMPROVED TENELIGLIPTIN AND METFORMIN COMPOSITION AND PROCESS TO PREPARE IT PE20190402A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2016010682A MX384961B (en) 2016-08-17 2016-08-17 IMPROVED COMPOSITION OF TENELIGLIPTIN AND METFORMIN AND PROCESS FOR PREPARING SAME.

Publications (1)

Publication Number Publication Date
PE20190402A1 true PE20190402A1 (en) 2019-03-13

Family

ID=61196457

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000305A PE20190402A1 (en) 2016-08-17 2017-06-23 IMPROVED TENELIGLIPTIN AND METFORMIN COMPOSITION AND PROCESS TO PREPARE IT

Country Status (8)

Country Link
AR (1) AR109253A1 (en)
CL (1) CL2019000273A1 (en)
CO (1) CO2019001110A2 (en)
DO (1) DOP2019000035A (en)
EC (2) ECSP19010066A (en)
MX (1) MX384961B (en)
PE (1) PE20190402A1 (en)
WO (1) WO2018033808A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014080383A1 (en) * 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Pharmaceutical composition of dipeptidyl peptidase-iv (dpp-iv) inhibitors in combination with other antidiabetics
WO2015132679A1 (en) * 2014-03-05 2015-09-11 Glenmark Pharmaceuticals Ltd Teneligliptin compositions

Also Published As

Publication number Publication date
CL2019000273A1 (en) 2019-06-28
AR109253A1 (en) 2018-11-14
DOP2019000035A (en) 2019-06-30
CO2019001110A2 (en) 2019-04-12
ECSP19010066A (en) 2019-11-30
WO2018033808A1 (en) 2018-02-22
ECSP19044926A (en) 2019-07-31
MX2016010682A (en) 2018-02-16
BR112019002909A2 (en) 2019-05-21
MX384961B (en) 2025-03-14

Similar Documents

Publication Publication Date Title
CL2018002009A1 (en) Compounds derived from cyclopentane perhydrophenanthrene, fxr modulators; pharmaceutical composition comprising said compounds; and its use for the treatment of cholestatic, fibrotic, hypercholesterolemia diseases, among others.
CO2019009215A2 (en) Hemi-sulfate nucleotide salt for the treatment of hepatitis C virus
MX2016008429A (en) DERIVED FROM PIRANOCROMENIL PHENOL, AND PHARMACEUTICAL COMPOSITION TO TREAT A METABOLIC SYNDROME OR INFLAMMATORY DISEASE.
MX2018011785A (en) INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE VIRAL REPLICATION OF DENGUE.
UY36340A (en) DERIVATIVES OF MONO- OR DISPOSED INDOLES AS INHIBITORS OF THE REPLICATION OF THE DENGUE VIRUS
CL2016001918A1 (en) Heteroaryl amides as protein aggregation inhibitors
PE20170470A1 (en) METHODS AND COMPOSITIONS TO TREAT OBESITY, PREVENT WEIGHT GAIN, PROMOTE WEIGHT LOSS, PROMOTE SLIMMING, OR TREAT OR PREVENT THE DEVELOPMENT OF DIABETES
ECSP15051434A (en) LOW DOSE PHARMACEUTICAL COMPOSITION
AR095032A1 (en) FORMULATIONS OF ORGANIC COMPOUNDS, SOLID PHARMACEUTICAL COMPOSITION COMPRESSED BY ROLLER
CO2017004994A2 (en) Substituted Bound Urea Analogs as Sirtuin Modulators
MX389553B (en) Composition for increasing expression of pgc-1î±
MX380531B (en) Peroxisome proliferator-activated receptor (PPAR) agonists, compounds, pharmaceutical compositions, and methods of using the same.
MX2017011499A (en) FIXED DOSE COMBINATIONS AND FORMULATIONS THAT INCLUDE ACID 8-HIDROXI-2,2,14,14 TETRAMETILPENTADECANODIOICO (ETC1002) AND EZETIMIBE AND METHODS TO TREAT OR REDUCE THE RISK OF CARDIOVASCULAR DISEASE.
ECSP19036192A (en) COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF THE BLACK SIGATOKA FUNGAL DISEASE IN BANANA CROPS
EA201892837A1 (en) PHYSIOLOGICALLY BALANCED COMPOUNDS FOR INJECTIONS, INCLUDING PHOSNET SUPPORTANT
PE20151746A1 (en) BICYCLE COMPOUNDS
CO2019004131A2 (en) Metformin glycinate, pharmaceutical compositions comprising the same, and methods of use thereof
PE20190452A1 (en) TRIAZOLOPYRAZINONE DERIVATIVE USEFUL AS AN INHIBITOR OF HUMAN PDE1
MX2018002298A (en) METHODS OF USE OF INTERLEUCIN 10 FOR THE TREATMENT OF DISEASES AND DISORDERS.
MX386902B (en) METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS.
PE20190402A1 (en) IMPROVED TENELIGLIPTIN AND METFORMIN COMPOSITION AND PROCESS TO PREPARE IT
AR105413A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISEASES
MX2018006631A (en) Compound for use in the prevention and treatment of neurodegenerative diseases.
NI202000017A (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES ACCOMPANIED BY DIABETES, INCLUDING AMLODIPINE, LOSARTAN AND ROSUVASTATIN, AND A COMPOSITE PREPARATION INCLUDING THE SAME
CL2020000251A1 (en) Derived from adamantylmethylamine and its use as a pharmaceutical product.